Deficits in locomotor behaviour and motor performance after central 6-hydroxydopamine or peripheral L-DOPA

Neurochemical Systems of the Retina Involved in the Control of Movement

Recent studies have revealed that the retina may exert control over deep brain function and may be importantly involved in the etiology, progression, and treatment of disorders such as Parkinson's disease (PD). While such a concept is uncharted territory and even less is known about the mechanism by which this might be achieved, this study was undertaken to determine how retinal dopamine (DA), serotonin (5-HT), and melatonin (MEL) neurotransmitter systems might be involved in the control of movement in their own right. To explore these further, intravitreal (IVIT) injections of DA, 5-HT, and MEL were made 0.5 or 3 h prior to testing horizontal and vertical movement in the open field as well as assessment on three motor tests used routinely to evaluate movement as a preclinical model of PD. The doses of DA (2 µl of 25 and 75 µg/µl), 5-HT (2 µl of 5 and 15 µg/µl), and MEL (2 µl of 5 µg/µl) were chosen because of previous work demonstrating an anatomically precise effect of these transmitters after they were injected directly into the brain. The postinjection times of testing were also chosen on the basis of previous intracerebral and IVIT work intimating the importance of the circadian cycle in determining the efficacy of such effects. 0.5 h after IVIT injection of DA at the 25 and 75 µg/µl doses, significant inhibition of motor function was observed. While IVIT injection of 10 or 30 µg of 5-HT also inhibited motor performance, this was significantly less than that seen with DA. In fact, IVIT injection increases motor performance compared to vehicle injection on some parameters. The IVIT injection of 10 µg of MEL facilitated motor function on many parameters compared to DA, 5-HT, and vehicle injection. When rats were tested 3 h after IVIT injection, the inhibition of vertical movement was also observed compared to controls. The present results illustrate that specific retinal neurotransmitter systems participate in the normal control of bodily motor function. The possible involvement of these systems in movement disorders such as PD is the subject of ongoing research.

L-Dopa− and Dopamine−(R)-α-Lipoic Acid Conjugates as Multifunctional Codrugs with Antioxidant Properties

A series of multifunctional codrugs (1-4), obtained by joining L-Dopa (LD) and dopamine (DA) with (R)-alpha-lipoic acid (LA), was synthesized and evaluated as potential codrugs with antioxidant and iron-chelating properties. These multifunctional molecules were synthesized to overcome the pro-oxidant effect associated with LD therapy. The physicochemical properties, together with the chemical and enzymatic stabilities of synthesized compounds, were evaluated in order to determine both their stability in aqueous medium and their sensitivity in undergoing enzymatic cleavage by rat and human plasma to regenerate the original drugs. The new compounds were tested for their radical scavenging activities, using a test involving the Fe (II)-H2O2-induced degradation of deoxyribose, and to evaluate peripheral markers of oxidative stress such as plasmatic activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) in the plasma. Furthermore, we showed the central effects of compounds 1 and 2 on spontaneous locomotor activity of rats in comparison with LD-treated animals. From the results obtained, compounds 1-4 appeared stable at a pH of 1.3 and in 7.4 buffered solution; in 80% human plasma they were turned into DA and LD. Codrugs 1-4 possess good lipophilicity (log P > 2 for all tested compounds). Compounds 1 and 2 seem to protect partially against the oxidative stress deriving from auto-oxidation and MAO-mediated metabolism of DA. This evidence, together with the "in vivo" dopaminergic activity and a sustained release of the parent drug in human plasma, allowed us to point out the potential advantages of using 1 and 2 rather than LD in treating pathologies such as Parkinson's disease, characterized by an evident decrease of DA concentration in the brain.

Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor

Over the past 10 years, there has been a resurgence of interest in examining the role of melatonin in health and disease. While the brunt of research in this area has portrayed melatonin in a favorable light, there is a growing body of evidence suggesting that melatonin may possess adverse effects contributing to the development of various neuropsychiatric disease states. In preclinical models of Parkinson's disease (PD), melatonin has been shown to enhance the severity of this condition while its antagonism, using constant light or pinealectomy, facilitates recovery. To test this hypothesis further, the present study employed the melatonin analogues ML-23 and S-20928 in a post-6-OHDA injection regime to determine whether they may have a favorable effect on the symptoms of this more chronic model of PD. When ML-23 was injected I.P. in a dose of 3 mg/kg twice daily for 3.5 days after 6-OHDA, significant improvement in motor function and regulatory deficits was observed. Similarly, the injection of S-20928 in a 1 mg/kg dose (I.P.), in the same regimen, facilitated modest improvement in motor function and regulatory deficits while the larger dose enhanced the severity of behavioural deficits and produced severe side effects causing deterioration in condition during the course of drug administration. ML-23 administration totally abolished the 6-OHDA-induced mortality, which accompanies dopamine (DA) degeneration, while S-20928 had no effect on this parameter. These results suggest that some melatonin analogues can aid in recovery from DA depleting lesions after DA degeneration has commenced and the recovery is not attributable to the antioxidative properties of this hormone. While the exact mechanism by which ML-23 and S-20928 are exerting their therapeutic effect is unclear, it is possible that antagonism of melatonin receptors may play some role and this should be considered when assessing the potential of melatonin analogues for treatment of human neuropsychiatric disorders.

The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function

There are reports that melatonin secretion from the pineal gland gradually diminishes with advancing age. It has been suggested that various forms of neuropsychiatric disease, in particular, Parkinson's disease (PD), is consequentially related to this decrease by virtue of increased oxidative stress which enhances the process of dopamine (DA) degeneration. There is, however, considerable disagreement on this theme as very little is generally known about the role of the pineal gland in the aetiology and treatment of PD. To assess the role of the pineal gland in PD and in dopamine replacement therapy (DART), the effect of three anti-Parkinsonian drugs on motor and psychiatric function was assessed in normal, pinealectomized (PX) and DA deficient, PX rats. In the first study, rats underwent PX or sham operation and were then injected (IP) with Amantadine (30 or 50 mg/kg), Bromocriptine (5 or 10 mg/kg) or L-Dopa (30 or 60 mg/kg plus 50 mg/kg of R-044602) 3-8 weeks after surgery. Open field performance and motor reflex tests were assessed during the light and dark phases of the L/D cycle. In a second study, clinically effective doses of Bromocriptine (10 mg/kg) and L-Dopa (30 and 100 mg/kg with 50 mg/kg R-044602) were injected into depleted, PX or sham operated rats. In study I, sham operated and PX rats responded differently to Bromocriptine and L-Dopa, while Amantadine did not differentially effect motor performance in the two groups. In study II, 6-OHDA induced degeneration of the nigro-striatal system abolished the effects of Bromocriptine and dramatically altered the effects of L-Dopa seen in study I, in sham operated versus PX rats. DART significantly altered emotionality, as measured by escape attempts, agitation and rage in sham operated animals, compared to PX rats. DA deficiency abolished the tendency to escape in all groups except those treated with 100mg/kg of L-Dopa. Conversely, agitation and rage scores were greater after 100 mg/kg of L-Dopa, in rats with intact pineal function, than in PX rats. These results provide compelling evidence that altered pineal function plays a major role in the aetiology of PD, the therapeutic effect of anti-Parkinsonian drugs and in the psychiatric side effects of DART.

Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease

The aetiology and treatment of Parkinsonism is currently conceptualised within a dopamine (DA) deficiency-repletion framework. Loss of striatal DA is thought to cause motor impairment of which tremor, bradykinaesia and rigidity are prominent features. Repletion of deficient DA should at least minimise parkinsonian signs and symptoms. In Section 2, based on extensive pre-clinical and clinical findings, the instability of this approach to Parkinsonism is scrutinised as the existing negative findings challenging the DA deficiency hypothesis are reviewed and reinterpreted. In Section 3 it is suggested that Parkinsonism is due to a DA excess far from the striatum in the area of the posterior lateral hypothalamus (PLH) and the substantia nigra (SN). This unique area, around the diencephalon/mesencephalon border (DCMCB), is packed with many ascending and descending fibres which undergo functional transformation during degeneration, collectively labelled 'orphan neurones'. These malformed cells remain functional resulting in pathological release of transmitter and perpetual neurotoxicity. Orphan neurone formation is commonly observed in the PLH of animals and in man exhibiting Parkinsonism. The mechanism by which orphan neurones impair motor function is analogous to that seen in the diseased human heart. From this perspective, to conceptualise orphan neurones at the DCMCB as 'Time bombs in the brain' is neither fanciful nor unrealistic [E.M. Stricker, M.J. Zigmond, Comments on effects of nigro-striatal dopamine lesions, Appetite 5 (1984) 266-267] as the DA excess phenomenon demands a different therapeutic approach for the management of Parkinsonism. In Section 4 the focus is on this novel concept of treatment strategies by concentrating on non-invasive, pharmacological and surgical modification of functional orphan neurones as they affect adjacent systems. The Orphan neurone/DA excess hypothesis permits a more comprehensive and defendable interpretation of the interrelationship between Parkinsonism and schizophrenia and other related disorders.

Ontogenetic development of the locomotor response to levodopa in the rat

Administration of exogenous levedopa triggers locomotion in young rats prior to the onset of quadripedal movement. The same substance decreases locomotion in adult animals. The ontogenetic development of the response to levodopa was investigated in rats. Intraperitoneal injection of levodopa (150 micrograms/kg body weight) caused characteristic "crawling" or "swimming-like" locomotion patterns in 5- to 6-day-old animals. Noradrenergic mechanisms may be involved in this behavior. In 18- to 20-day-old rats, levodopa caused excessive locomotor activity, including running, jumping, and wall climbing. This effect can be attributed to the activation of postsynaptic dopaminergic receptors that are already present during the early stages of life. At 25-30 days of age, levodopa-induced motor activity was decreased in comparison with that of the 18- to 20-day-old rats, possibly due to changing patterns of D1/D2-dopamine receptor subtype interactions. In contrast to observations in younger rats, the same dose of levodopa suppressed motor activity in 60- to 75-day-old rats. The presence of functional dopamine autoreceptors at this age may account for the change.

The lateral hypothalamic area revisited: ingestive behavior

This article discusses the role of the lateral hypothalamic area (LHA) in feeding and drinking and draws on data obtained from lesion and stimulation studies and neurochemical and electrophysiological manipulations of the area. The LHA is involved in catecholaminergic and serotonergic feeding systems and plays a role in circadian feeding, sex differences in feeding and spontaneous activity. This article discusses the LHA regarding dietary self-selection, responses to high-protein diets, amino acid imbalances, liquid and cafeteria diets, placentophagia, "stress eating," finickiness, diet texture, consistency and taste, aversion learning, olfaction and the effects of post-operative period manipulations by hormonal and other means. Glucose-sensitive neurons have been identified in the LHA and their manipulation by insulin and 2-deoxy-D-glucose is discussed. The effects on feeding of numerous transmitters, hormones and appetite depressants are described, as is the role of the LHA in salivation, lacrimation, gastric motility and secretion, and sensorimotor deficits. The LHA is also illuminated as regards temperature and feeding, circumventricular organs and thirst and electrolyte dynamics. A discussion of its role in the ischymetric hypothesis as an integrative Gestalt concept concludes the review.

Amine accumulation: a possible precursor of Lewy body formation in Parkinson's disease

It is now well recognized that the hypothalamus is an important site of neuropathology in Parkinson's disease (PD). Lewy bodies, a marker of nerve cell degeneration and a pathological hallmark of PD, have been observed frequently in the hypothalamus of PD patients by Lewy (1923) and other investigators and confirmed by more recent systematic studies by Langston & Forno (1978). Both Lewy and Langston & Forno found a predilection of Lewy body formation in specific hypothalamic nuclei with the tuberomammillary, lateral, and posterior areas containing by far the highest average counts per nucleus. Selective vulnerability of the tuberomammillary, lateral, and posterior hypothalamic cell groups to degeneration has been observed also in aging, postencephalitic Parkinsonism, Alzheimer's disease, and schizophrenia. The susceptibility of these particular nuclei to degenerative changes including Lewy body formation is not presently understood nor are the mechanisms by which Lewy bodies are formed in PD and other CNS disorders. Accumulation of amines, a pathological process which follows degeneration of catecholamine-containing neurons in experimental animals, also occurs most frequently in the lateral and posterior hypothalamic areas. In the present communication we propose that in PD, amine accumulation may be a precursor to Lewy body formation and that the susceptibility of certain hypothalamic areas to Lewy body formation may be related to their propensity to accumulate amines. Furthermore, the frequent co-existence of Lewy bodies and Alzheimer's neurofibrillary tangles in the lateral and posterior hypothalamic nuclei suggest that they may share a common pathogenetic etiology. If confirmed, this hypothesis may provide an experimental model by which the formation of Lewy bodies and neurofibrillary tangles may be investigated.

Sensitivity of dopamine receptors in the lateral hypothalamus is altered in 6-hydroxydopamine treated rats

Amine accumulation is observed in the lateral hypothalamus (LH) after nigrostriatal neurons degenerate. It has been proposed that this accumulation is a source of amines which are released into the hypothalamus thereby affecting the function of adjacent aminergic receptors. To approximate this condition of continuous exposure of LH receptors to endogenous amines, dopamine (DA) was injected into the LH of rats once daily for 5 consecutive days. A control group received 4 daily injections of tartaric acid vehicle and then DA on day 5. Rats pretreated with DA showed severe impairment of open field performance and motor reflex control on day 5 when they were compared to control animals which received vehicle pretreatment. In a second study, the DA receptor antagonist haloperidol was injected into the area of amine accumulation in the LH to determine whether this might block amine release from areas of accumulation thereby to attenuate lesion-induced rotation. Haloperidol administered once daily for 4 out of 7 days, once daily for 7 days or via a continuous infusion for 7 days, all reduced d,l-amphetamine-induced turning to control levels. These results suggest that prolonged exposure of hypothalamic DA receptors alters their sensitivity to subsequent doses of DA and that amine released from areas of accumulation may be blocked by haloperidol to enhance behavioral recovery from DA depleting lesions. Moreover, these findings indicate that the hypothalamus participates in the behavioral effects induced by DA depleting lesions and highlight the importance of hypothalamic pathology in Parkinson's disease.

Amelioration of experimental parkinsonism by intrahypothalamic administration of haloperidol

Accumulation of amines in the degenerating axons of ascending catecholamine-containing neurons in the hypothalamus has been proposed as a site of function neurotransmitter release and may thereby participate in the development of motor impairment seen after central dopamine-depleting lesions. To test this hypothesis further the dopamine receptor antagonist haloperidol (1 microL of a 14 nmol solution) was injected directly into the lateral hypothalamus (LH) in 6 different injection regimes to determine whether amphetamine-induced turning could be attenuated with this treatment. The injection of haloperidol at 1 and 24 h (group 1), 24 h (group 2) or 6+ 7 d (group 3) after 6-hydroxydopamine (6-OHDA) did not modify amphetamine-induced turning. However, the injection of haloperidol at 1 h, 24 h, 7 d, and 8 d (group 4), days 1-7 (group 5), or gradual infusion (14 nmol/microliters/h) for 7 days (group 6) all reduced the 6-OHDA-induced turning to a level similar to that of controls. These results add further support to the contention that amines are released from the axons of degenerating neurones in the hypothalamus and that this phenomenon participates in the elicitation of behavioral impairment attributed solely to the loss of functional neurotransmitters from terminal fields. Furthermore, the data emphasize the importance of hypothalamic pathology in the development of Parkinsonism and suggest that intrahypothalamic administration of dopamine blocking agents might be useful in the treatment of Parkinsonism.

Amine accumulation, catecholamine depletion and motor impairment in Macaca fasicularis and the C-57 black mouse after MPTP administration

1. Macaca fasicularis monkeys and C-57 black mice were injected with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in different injection regimes. 2. The performance of monkeys on a rapid alternating movement task was measured before, during and after drug injection. 3. The open field performance of C-57 black mice was assessed 0.5hr, 24hr and 7 days after the completion of the injection regime. 4. Only the monkey receiving the 2mg/kg dose over 8 days displayed progressive akinesia and muscular rigidity. 5. Only a very slight impairment of motor function was seen in the C-57 black mice 0.5hr after injection. 6. Fluorescent histochemical analysis revealed that while striatal depletion was severe in monkeys and mice, accumulation of amines was seen only in the brain tissue of the severely impaired monkey. 7. Degeneration-associated increases in amines are important in the aetiology of Parkinsonian-like motor impairment produced by selective neurotoxins across different species.

The function of lateral hypothalamic catecholamine and endorphin systems in the control of motor performance

Morphine (1 or 10 micrograms in 1 microliter) or beta-endorphin (1 microgram in 1 microliter) were injected bilaterally into the posterior lateral hypothalamus of Sprague-Dawley rats to determine what effect they may have on motor performance. Severe reductions in open field performance and motor reflex control were observed after the injection of 1 microgram of beta-endorphin or morphine into this area. The injection of 10 micrograms of morphine into the same area was less effective in causing motor impairment. The central (32.7 micrograms in 1 microliter) and peripheral (2 mg/kg) injection of naloxone did not prevent the motor impairment observed after the injection of beta-endorphin or morphine. Pretreatment with 6-hydroxydopamine into the lateral hypothalamus in a multistage regime did not prevent the motor impairment observed after beta-endorphin or morphine injection. These results indicate that lateral hypothalamic participation in the control of motor function may not involve the ascending nigrostriatal and mesocortical dopamine systems and that endogenous opiate systems may function independently to influence motor performance.

MPTP, impairment of motor performance and amine accumulation in Macaca fascicularis

The selective neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was injected (IV) into monkeys (Macaca fascicularis) in two different injection regimes. With the small dose regime, one monkey was injected with 0.25 mg/kg, every other day, over a 16 day period. In the large dose regime, another monkey was injected with 0.5 mg/kg every other day, over an 8 day period. While the time required for drug delivery was varied between animals, the total dose delivered was 2 mg/kg in both animals. Before, during and for 14 days after the course of drug administration both animals were assessed on several motor function tests. The animal receiving the small dose regime showed normal motor performance on all tests for the duration of the study, however, the monkey receiving the large dose regime displayed progressive akinesia, muscular rigidity, and aphagia. In fact, impairment was so severe that this animal had to be force fed and maintained with daily oral L-dopa. Fluorescent histochemical assessment of forebrain in both monkeys revealed that striatal tissue was totally devoid of fluorescence in both cases. Large, swollen axons in the internal capsule, hypothalamus and midbrain were visible only in the severely impaired animal. These results suggest that, as with other neurotoxins, degeneration associated increases in amines may be important in the aetiology of Parkinson-like motor impairment produced by selective neurotoxins.

Amine accumulation in Parkinson's disease and other disorders

Amine accumulation in the axons of degenerating, amine-containing neurones is a natural component of neurone death in many species, including man. While it is becoming increasingly clear that this phenomenon may have functional significance in animal models of Parkinson's Disease, its potential importance in the clinical syndrome has been pretermitted. There are several reasons for this. Failure to sample tissue which contains accumulated amines, the masking of accumulation by adjacent depleted tissues and the degradation of accumulated amines in post-mortem tissues from Parkinsonian brains could account for the low incidence of detection of accumulation in this disorder. Increased levels of amines have been detected in the brains of patients with other conditions including cerebral infarction, Alzheimer's Disease and Huntington's Chorea. These increases have been attributed previously to enhanced aminergic activity, rather than a stage in the degenerative process, as our hypothesis suggests. In addition to the potential importance of amine accumulation in the pathophysiology of various clinical syndromes, a more thorough investigation of this phenomenon in animal models would seem essential since they are used routinely to both describe the basic principles of dopamine function and to evaluate therapeutic possibilities in Parkinson's Disease.

Further studies on the neurochemical specificity of 6-hydroxydopamine as compared to radiofrequency lesions

Despite the large volume of literature during the past 15 years addressing the problem concerning the neurochemical specificity of 6-hydroxydopamine (6-OHDA), there is still disagreement over this issue. While some claim that the catecholamine-specific effects of this drug can be maximized by controlling the dose injected, others claim that all doses of 6-OHDA produce non-specific damage (NSD), thereby contraindicating its use in experimental paradigms. In the present study, we examined the degree of neurochemical specificity of 6-OHDA by comparing the volume of proximal accumulation to that of NSD, produced by 6-OHDA (2 microliter of 8 micrograms/microliter) or radiofrequency (RF) lesions (60 degrees C for 50 s and 45 degrees C for 30 s), placed in the medial forebrain bundle. The volume of NSD and accumulation produced by 6-OHDA was significantly less than that produced by large RF lesions which had a similar effect on the gross behaviour of albino rats. Smaller RF lesions produced similar volumes of NSD but less amine accumulation than did 6-OHDA, and did so without affecting normal behaviour. The ratio of NSD to accumulation in 6-OHDA treated rats was 3/1, while large and small RF lesions produced a NSD/accumulation ratio of 15/1. The present study introduces a novel method of determining the degree of neurochemical specificity which can be achieved with 6-OHDA and reveals that it is several magnitudes more neurochemically specific than RF lesions.

Amine accumulation in behavioural pathology

When nigro-striatal and meso-cortical neurons degenerate there is a loss of dopamine in the terminal fields and an accumulation of amines in the axons of these systems as they traverse the hypothalamus through the medial forebrain bundle. Traditional lines of thought have attributed the occurrence of motor and consummatory deficits which occur after dopamine neuron degeneration to the loss of functional dopamine neurotransmitter in the terminal fields. However, we have hypothesized that hypothalamic amine accumulation represents an area of brain tissue where processes such as neurotransmitter release, ephaptic transmission or local axon swelling may be affecting adjacent neurons and may thereby participate in the production of behavioural deficits. There is a considerable amount of evidence from studies on both peripheral and central catecholamine-containing neurons indicating that when their axons degenerate a release of functional neurotransmitter can occur. Information from neuropharmacological studies indicates that several drugs which facilitate behavioural recovery from dopamine-depleting lesions may do so by affecting amine release or receptor sensitivity near areas of accumulation rather than depleted terminal fields. We conclude that amine accumulation is a component of dopamine neuron degeneration which should be considered when assessing the role of the central catecholamine systems in the control of various behavioural and physiological processes.

Microspectrofluorometric characterization of amine accumulation proximal to lateral hypothalamic lesions

Microspectrofluorometry was employed to identify the spectral characteristics of the formaldehyde-induced fluorophore derived from amine accumulation proximal to the site of 6-hydroxydopamine injection or radiofrequency lesions in the lateral hypothalamus of Sprague-Dawley rats. The excitation and emission spectra of the accumulation were consistent with that of catecholamines in models subjected to similar formaldehyde treatment. These results indicate that while biochemical assay technique may not permit the quantification of amine accumulations, these areas do in fact represent degeneration associated increases in catecholamines which may be of functional significance.

Catecholamine-blocking drugs injected at sites of amine accumulation reverse catecholamine degeneration associated deficits

It has been hypothesized that catecholamine (CA) accumulation in the axons of degenerating neurons may represent areas of functional neurotransmitter, and may be producing some of the consummatory and locomotory deficits which occur after central CA-depleting lesions. To test this hypothesis further, haloperidol (0.5 microliter of a 7 nM sol.), propranolol (0.5 microliter of a 175 nM sol.) or isotonic saline (0.5 microliter) were injected 1.5 h, 24 h and 48 h after the injection of 6-hydroxydopamine (6-OHDA; 2 microliter of 8 micrograms/microliters) into the lateral hypothalamus (LH) of Sprague-Dawley rats to determine if the hypothermia, motor impairment and consummatory deficits could be reversed. Although haloperidol injection significantly enhanced the hypothermia seen 1.5 h after 6-OHDA injection, open field performance and consummatory responses were significantly improved after haloperidol was injected into the LH where accumulation is known to occur. Three consecutive days of intracerebral haloperidol treatment produced a recovery of body weight regulation lasting for 6 days. Treatment with propranolol enhanced open field performance 1 day after 6-OHDA injection but failed to enhance recovery of consummatory behaviour and body weight control. These results suggest that CA released from areas of accumulation act on adjacent CA receptors to participate in the production of behavioural deficits previously attributed only to the loss of functional neurotransmitter in terminal fields in the forebrain.

The masking of amine accumulation by catecholamine depletion

6-Hydroxydopamine (2 microliter of 8 micrograms/microliter) was injected bilaterally into the lateral hypothalamus of male Sprague-Dawley rats to produce depletion of forebrain terminal fields and an accumulation of amines proximal to the site of injection. Two additional groups of animals were injected with either vehicle or were food and water intake-matched to those receiving 6-hydroxydopamine. Motor performance, food and water intake and body weight were measured in all animals for 2 days before and 6 days after injection. Animals were then sacrificed and brain tissue was prepared for biochemical assay or fluorescence histochemistry. The area of hypothalamic tissue proximal to 6-hydroxydopamine injection, that which contains the amine accumulation, was sectioned from the surrounding tissue with a biopsy punch and assayed for noradrenaline and dopamine content. The nucleus caudatus-putamen, basomedial hypothalamus, and tissue containing the olfactory tubercle and accumbens nucleus were also assayed. Fluorescent histochemical examination of tissue showed that in addition to the depletion of catecholamines in various terminal fields there was also an increase in the fluorescent amine accumulation proximal to the injection site in the impaired animals. This accumulation was not detected with the biochemical assay and is probably due to the occurrence of a masking effect by adjacent depletions. A significant rise in noradrenaline levels was seen in the basomedial hypothalamus of intake-matched controls. However, this too was not detected in 6-OHDA-treated animals and was probably due to masking by adjacent depletions in these areas.(ABSTRACT TRUNCATED AT 250 WORDS)

A role for amine accumulation in the syndrome of ingestive deficits following lateral hypothalamic lesions

Lesions of the lateral hypothalamus produce ascending catecholamine neuron degeneration which results in terminal depletion and proximal accumulation above the lesions. The occurrence of deficits in ingestive behaviour has been attributed traditionally to the loss of functional dopamine neurotransmitter in the terminal fields. However, release of functional amines may occur in the lateral hypothalamus at areas of accumulation, to produce at least some of the behavioural symptoms characterizing the lateral hypothalamic syndrome. Recovery from behavioural deficits as a result of various pharmacological treatments, after dopamine-depleting lesions, may be mediated by changes in amine release or modified sensitivity of receptors affected by released amines. We conclude that amine accumulation should be considered when interpreting experiments implicating central catecholamine systems in the control of consumatory behaviour and the regulation of body weight.

Ventricular, paraventricular and circumventricular structures involved in peptide-induced satiety

Cholecystokinin, bombesin or gastrin (2 microliter of 50 ng/microliter) was injected stereotaxically into the paraventricular nucleus of the hypothalamus, the arcuate/ventromedial area, the subfornical organ, the area postrema and the cerebral aqueduct of Sprague-Dawley rats and the effects of these injections on food and water intake were studied. While the injection of cholecystokinin reduced food intake when it was injected into both hypothalamic loci, food and water intake were most severely affected by the injection of this peptide into the cerebral aqueduct. Bombesin reduced food intake after its injection into all areas except the subfornical organ and reliable reductions in water intake were seen after injection of this peptide into all areas except the paraventricular nucleus. Minor reductions in food intake were seen following gastrin injection into the paraventricular nucleus while increased water consumption was observed after this peptide was injected into the paraventricular nucleus and cerebral aqueduct. In a second study 6-hydroxydopamine injections (2 microliter of 8 micrograms/microliter were made into the five areas studied 10 days before animals were injected with 100 micrograms/kg of cholecystokinin (i.p.). All 6-hydroxydopamine-injected animals reduced their food and water intake in response to the cholecystokinin challenge as did intact controls. These results indicate that while the changes in food and water intake produced by the central injection of cholecystokinin, bombesin or gastrin may involve central catecholamine systems, those occurring after its systemic administration do not. Therefore, if the release of gastrointestinal peptides during natural feeding is part of a homeostatic mechanism regulating hunger and satiety, this mechanism may operate without directly involving central catecholamine systems.

Dopamine-rich transplants in rats with 6-OHDA lesions of the ventral tegmental area. I. Effects on spontaneous and drug-induced locomotor activity

In order to investigate the relative contribution of dopaminergic projections to the nucleus accumbens and prefrontal cortex in the regulation of spontaneous and drug-induced locomotor activity, separate groups of rats were prepared with 6-OHDA lesions of the ventral tegmental area alone, or additional grafts of dopamine-rich tissue reinnervating either the nucleus accumbens or medial prefrontal cortex. A fourth unoperated group served as normal controls. The lesions induced no change in spontaneous, daytime activity, but increased overnight activity. The lesioned rats were also hyperactive to apomorphine, while the activational effects of amphetamine were blocked. Grafts of dopamine-rich tissue, whether into the prefrontal cortex or nucleus accumbens, resulted in a significant normalization of both drug responses towards control levels. Neither graft influenced overnight hyperactivity, whereas spontaneous daytime activity was increased above both control and lesion levels by the accumbens grafts alone. The results are interpreted as suggesting that dopaminergic projections to prefrontal cortex and nucleus accumbens are similarly rather than antagonistically involved in the regulation of drug-induced locomotor activation.

Deficits in locomotor behaviour and thermoregulation produced by intrahypothalamic dopamine injections

When nigrostriatal dopamine neurones degenerate, a loss of functional dopamine in the striatum occurs and is accompanied by increased dopamine in the degenerating axons which traverse the hypothalamus. While the behavioural deficits which occur after nigrostriatal degeneration have been attributed to the loss of functional dopamine neurotransmission, evidence produced by us suggests that the increased levels of amines in the degenerating axons may be neuroactive and participate in the production of these behavioural deficits. To test this hypothesis further, albino rats were injected bilaterally with 200 nmol of dopamine in a location just rostral to the diencephalon/mesencephalon border, where amine accumulation is commonly observed following lateral hypothalamic damage. The effect of these injections upon open field performance, thermoregulation and motor reflex control was determined 40 min after dopamine injection. In a second study, pargyline (15 mg/kg. i.p.) was administered 30 min before intracerebral dopamine to determine whether this treatment would increase the severity of motor and thermoregulatory deficits which occurred after dopamine injections alone. Deficits in locomotion, rearing and the ability to regulate body temperature were seen after the dopamine injections while motor reflex control in these animals was similar to that seen in vehicle-injected controls. The behavioural deficits displayed by pargyline pretreated, dopamine injected animals were slightly but not significantly more severe than those displayed by animals receiving dopamine injections alone. Fluorescent histochemical assessment of injection sites revealed that dopamine injection produced an increase in fluorescence or "amine accumulation" at the site of injection but this was considerably less than that seen after catecholamine degeneration.(ABSTRACT TRUNCATED AT 250 WORDS)